IRCT20220702055337N1 IRCT 2022-09-16 Arak University of Medical Sciences The effect of amikacin in the prevention of ventilator-induced pneumonia The effect of amikacin in the prevention of ventilator-induced pneumonia in patients admitted ICU 2022-09-21 anticipated 126 Complete https://irct.ir/trial/65846 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Randomization description: Patients will be randomly divided into two groups by block method in the form of blocks of 4. Blocking and allocation sequence will be done by a person not involved in the research, and they will be in two groups receiving amikacin antibiotic and control. Then, based on the obtained blocks and according to the allocation sequence, the medicine will be given to the patients, Blinding description: According to the double blind study, in this study the patients and also the data analyst and the intern of the project partner who is responsible for completing the questionnaires will be unaware of the division. 3 Pneumonia. Intervention 1: Intervention group: Patients who undergo invasive ventilation for more than 3 days are randomly divided into two groups: Intervention group: amikacin powder without sulfite (Caspian Pharmaceuticals, Tamin, Iran) in sterile water (1 gram per 8 ml) liter) will be dissolved and inhaled once a day for 3 days at a dose of 20 mg/kg based on the estimated body weight. Intervention 2: Control group: plasbo inhalation (0.9% sodium chloride) is used by inhalation daily for 3 days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is The release schedule is not yet known